Changes in Hong Kong stocks | Sansheng Pharmaceutical (01530) rose more than 3%, a subsidiary of Sansheng Mandy and Deruizhi Pharmaceutical reached an exclusive MDR-001 cooperation

Zhitongcaijing · 3d ago

The Zhitong Finance App learned that Sansheng Pharmaceutical (01530) rose by more than 3%. As of press release, it had risen 3.54% to HK$32.74, with a turnover of HK$15.4.36,800.

According to the news, according to the official WeChat account of Sansheng Pharmaceutical, on September 28, Zhejiang Sansheng Mandy Pharmaceutical Co., Ltd. (hereinafter referred to as “Mandi”) and Wansheng Pharmaceutical (hereinafter referred to as “Wansheng”) announced that they have reached an exclusive commercial cooperation with Hangzhou MindRank Technology Co., Ltd. (MindRank, hereinafter referred to as “Derui Zhi”) on their self-developed AI design oral small molecule GLP-1 receptor agonist covering mainland China, Hong Kong, and Macau. MDR-001 is currently conducting a phase III key clinical study in China for adults who are obese or overweight.

According to the agreement, Sansheng Mandy and Wansheng Pharmaceutical will pay a maximum of RMB 150 million in cooperative rights payments (including down payment, regulatory approval, initial commercial delivery, and cooperative rights payments for additional indications), and up to RMB 1.6 billion in concession use payments after meeting the agreed conditions. The total potential transaction amount will not exceed RMB 1.75 billion.